Kornimate/medical-research-clean huggingface dataset:
social skills training in refractory schizophrenia

Conditions: Schizophrenia and Disorders With Psychotic Features

Summary: objective primary: to evaluate the efficacy of social skills training in reducing negative symptoms in patients with refractory schizophrenia, in comparison with control (befriending group). secondary: to evaluate changes in social functioning. to evaluate the effect of sst in other dimensions of psychopathology: positive symptoms, depression and general psychopathology. to evaluate the impact of sst in cognition. hypothesis social skills training is more effective than control group (befriending) in reducing negative symptoms in patients with refractory schizophrenia.

in schizophrenia positive symptoms can be improved with an antipsychotic treatment. however there is a subgroup of patients who have a predominance of persistent negative symptoms that do not respond to antipsychotic treatment, such as blunted affect , emotional and social withdrawal, and there is evidence that such symptoms can improve with psychosocial interventions. the objective of this study is to evaluate the efficacy of social skills training on negative symptoms in patients with refractory schizophrenia by means of a randomized, single-blind controlled trial with the duration of a year, including, follow up. this study will be conducted in two groups: one group will receive social skills training (n=46) and a control group (n=46) will attend the same number of sessions, but without intervention of the therapists (befriending). psychiatric, psychological and neuropsychological aspects will be evaluated at baseline, after 20 weeks and 6 months after the end of the intervention. the scales that will be used for the psychiatric assessments are: panss (reduction of 20% in the negative subscale), cgi, calgary, sds, and psp, as well as the social skills inventory ihs. the neuropsychological assessment will have groups of scales to measure: attention, memory, executive functions, estimated intellectual efficiency and a tom. for statistical , the repeated measure anova will be used, as well as the effect size and number needed to treat.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia can´t not be over 10 years old. * age between 18 and 55 years old. * a minimum of 16 in negative subscale of panss. * a score 4 in at least 3 of the following symptoms: * blunted affect * social withdrawal * rapport * passive social withdrawal * lack of spontaneity * motor retardation * active social avoidance * stable disease, in use of clozapine, without recent hospitalization. exclusion criteria: * comorbid substance use. * axis i comorbidity. * history of head trauma or neurological disease. * clinical problems which can affect central nervous system. * mental retardation. * patients treated with other antipsychotic than clozapine. * patients who underwent other psychosocial treatments.
collection of clinical specimens from volunteers for assay development

Conditions: Acute Respiratory Infection

Summary: this study will analyze gene expression data from various biological specimens collected from voluntary participants.

primary objective is the collection of specimens from volunteers for the development and validation of hostdx tests. the study does only encompass specimen collection - therefore, no traditional endpoint is defined but rather the successful collection of clinical specimens is defined as the endpoint.

Eligibility criteria:
inclusion criteria: * 18 years of age or greater * able to provide informed consent exclusion criteria: * known pregnancy * inability to understand instructions and comply with study related procedures
mailed reminders plus fecal immunochemical testing

Conditions: Colorectal Cancer Screening; Colorectal Cancer

Summary: purpose: the investigators propose to test the effectiveness, feasibility, and cost-effectiveness of a mailed reminder with and without fit kits in a population of medicaid enrollees in mecklenburg county.

purpose: the investigators propose to test the effectiveness, feasibility, and cost-effectiveness of a mailed reminder with and without fit kits in a population of medicaid enrollees in mecklenburg county. participants: medicaid beneficiaries who are enrolled in community care of north carolina, ages 52-64, currently living in mecklenburg county, at average risk for colorectal cancer (crc), with no record of recent crc screening (fobt within 12 months, colonoscopy within 10 years). procedures (methods): participants will be identified through the state medicaid database and randomized to receive either: 1) a mailed reminder to complete crc screening including a fit kit, instructions for completion, and a return mailer, or 2) a mailed reminder to complete crc screening only. any recipients testing positive will be guided by care managers from community care of north carolina to ensure a follow-up colonoscopy is completed.

Eligibility criteria:
inclusion criteria: 1. current medicaid beneficiary, 2. enrolled in community care partners of greater mecklenburg (ccpgm), 3. 52-64 years old, 4. english or spanish speaking, 5. no record of fobt/fit within 12 months or colonoscopy with 10 years, sigmoidoscopy within 5 years; barium enema within 5 years, ct colonography within 10 years, 6. no record of any crc diagnosis or total colectomy exclusion criteria: 1. \ 64 years of age; 2. history of colorectal cancer or total colectomy (see attached table for codes), 3. persons dually enrolled in medicare, 4. not enrolled in ccpgm, 5. received fobt or fit within 12 months; colonoscopy within 10 years; sigmoidoscopy within 5 years; barium enema within 5 years, ct colonography within 10 years

Keywords: colorectal cancer screening colorectal cancer
myofunctional training for obstructive sleep apnea patients after transoral robotic surgery

Conditions: Sleep Apnea, Obstructive

Summary: background: obstructive sleep apnea syndrome (osa) is a kind of sleep disorder. the symptoms are intermittent, partial or complete upper airway collapse, seriously impacting oxygen saturation and oxidative stress. some patients choose to do upper airway surgeries, but the success rate is only 60-70%. the symptoms might relapse because of aging and gaining weights. the purpose of our study is to compare the effect of transoral robotic surgery (tors) and oropharyngeal rehabilitation (opr) on patients after tors. methods: participants above 20 years old who are newly diagnosed with mild to severe osa (apnea-hypopnea index \>5/h), and the physician will explain the treatment programs to every subject in clinic. expected results: the hypothesis of this study is the success rate of surgery will be enhance by increasing tongue and jaw-opening muscle strength after opr. the biomarkers of cardiovascular disease may decrease and both the collapse of upper airway and sleep quality may be improved after tors and opr.

the participants above 20 years old who are newly diagnosed with mild to severe osa (apnea-hypopnea index \>5/h), and the physician will explain the treatment programs to every subject. by their willingness to choose the therapeutic method, the participants who select the surgery interventions will be assign to tors or tors+opr group. the matched controls as well as age-, sex-, and body mass index-matched osa participants will be selected from the patients who are waiting for oral appliance, losing weight and using continuous positive airway pressure. before surgery, 6 week and 18 week after surgery, the investiagters will compare the polysomnography data, questionnaires of sleep quality, drug-induced sleep endoscopy and computed tomography as primary outcomes. the investigators will also compare the tongue and jaw-opening muscle strength and biomarkers of oxidative stress, anti-oxidative stress, inflammatory cytokines and matrix metalloproteinases 9 as secondary outcomes. the opr would begin at 6 week after surgery, and participants will undergo three months of the home-based oropharyngeal myofunctional therapeutic training. during the training intervention period, participants will be interviewed one time per week for adjusting the treatment intensity.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild to severe osa in the past year * age between 20-65 years old. exclusion criteria: * a history of malignancy or infection of the head and neck region and laryngeal trauma * craniofacial malformation * stroke * neuromuscular disease * heart failure * coronary artery disease.
radical prostatectomy and external beam radiotherapy in mcrpc with 223radium-dicloride (raprorad)

Conditions: Prostate Cancer

Summary: the investigators provided a multicenter analysis aiming to investigate, in a clinical practice setting, the prognostic relevance of previous primary radical prostatectomy (rp) or external beam radiotherapy (rt) in terms of overall survival as opposed to patients with no primary treatment performed, in a cohort of patients enrolled in 223-ra treatment for mcrpc. 223-ra has been administered from investigators according to the current label authorization and all patients underwent 223-ra treatment, until disease progression or unacceptable toxicity.


Eligibility criteria:
inclusion criteria: * histological confirmation of prostatic adenocarcinoma, at least two symptomatic bone secondary lesions detected by bone scan and no known visceral metastases, except for malignant lymphadenopathy with less than 3 cm in the short axis diameter exclusion criteria: * eastern cooperative oncology group (ecog) performance status (ps) score \>2 and inadequate hematological, hepatic and renal function

Keywords: 223-radium-dicloride radical prostatectomy overall survival
a study to assess the effects of pt003 and placebo mdi on specific image based airway volumes and resistance in subjects with moderate to severe copd

Conditions: COPD

Summary: study to evaluate the effects of pt003 and placebo mdi on specific image based airway volumes and resistance with moderate to severe copd.

enrolled patients with copd who were randomized to receive either pt003 mdi or placebo mdi first and then crossed over to receive the opposite intervention. the study consisted of 2 treatment periods of 14 days separated by a washout period of 5-21 days.

Eligibility criteria:
inclusion criteria: * non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or child bearing potential, has a negative urine pregnancy test at visit 1 and agrees to an acceptable method of contraception * subjects with an established clinical history of copd as defined by the american thoracic society (ats)/european respiratory society (ers) * current or former smokers with a history of at least 10 pack-years of cigarette smoking. * at visit 1, fev1/fvc ratio must be \<0.70 * at visit 1, post-bronchodilator fev1/fvc ratio of \<70% and fev1 must be 30% to 80% before predicted normal value, calculated using nhanes iii reference equations. exclusion criteria: * significant diseases other than copd, i.e., disease or condition which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study. * women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception. * subjects, who in the opinion of the investigator, have a current diagnosis of asthma. * subjects who have been hospitalized due to poorly controlled copd within 3 months prior to visit 1 (screening) or during the run-in period (visit 1 to visit 2). * subjects who have poorly controlled copd, defined as acute worsening of copd that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to visit 1 (screening) or during the run-in period (visit 1 to visit 2). * subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated. * subjects who have a history of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic anticholinergics, or any component of the mdi. please refer to the study protocol for the complete inclusion criteria list.
the effect of "adjacent bed effect" induced by anxiety on the perioperative period of patients with chocolate cyst of ovary

Conditions: Participants' Pain,Quality of Life and Hospital Satisfaction

Summary: the "adjacent bed effect" caused by anxiety leads to poor recovery of participants after ovarian chocolate cyst surgery, including pain and quality of life, and affects participant satisfaction with the hospital.


Eligibility criteria:
inclusion criteria: 1. ovarian chocolate cyst diameter ≥4cm; 2. infertility; 3. dysmenorrhea medications were ineffective; any one of the above, with or without clinical symptoms. exclusion criteria: 1. age \<18 years old; 2. previous history of other surgeries; 3. previous history of nervous system diseases, such as parkinson's disease, dementia, etc. 4. previous history of blood system diseases, such as leukemia; 5. unable to tolerate surgery due to serious complications, such as serious cardiovascular and cerebrovascular diseases; 6. inability to complete the questionnaire due to language or learning disabilities; 7. those who don't want to participate.
the effect of glp-1 on postprandial glucagon secretion independent of the gastric emptying rate

Conditions: Type 1 Diabetes

Summary: aim: to investigate the glucagonostatic effect of glucagon-like peptide-1 (glp-1) independent of the gastric emptying rate.

aim: to investigate the glucagonostatic effects of glucagon-like peptide-1 (glp-1) during prolonged and intermittent stimulation of the glp-1 receptor independent of the gastric emptying rate. glucagon concentrations will be measured following a liquid meal administered in duodenum at baseline and after exenatide, and liraglutide treatment.

Eligibility criteria:
inclusion criteria: * type 1 diabetes * \>18 years * no residual beta-cell function (stimulated c-peptide \< 60 pmol) exclusion criteria: * pancreatitis * gastroparesis * history of alcohol and/or drug abuse * pregnancy and lactation * other medical or psychological condition that made the patient unsuitable for study participation according to the investigators´ assessment * contraindications to gastroscopy * cancer (unless in complete remission \> five years)

Keywords: glucagon glukagon-like peptide-1 (glp-1) glp-1 receptor agonist (glp-1ra) incretins
blood biomarkers in pediatric kidney transplant recipients

Conditions: Rejection of Kidney Allograft

Summary: the objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody mediated rejection. the study hypothesizes that blood gene expression profile and donor-derived cell-free dna biomarkers (omnigraf) can be used to predict acute rejection and monitor its response to treatment.


Eligibility criteria:
inclusion criteria: * kidney transplant recipients * participants undergoing a for-cause kidney biopsy to rule out graft rejection * ages 21 years and less exclusion criteria: * participants who have opted out of research * patients, less than 18 years of age, whose parents or legal guardians are illiterate and cannot read. * participants, 18 years and older, who are illiterate and cannot read. * participants, less than 18 years of age, whose parents or legal guardians do not speak english. * participants, 18 years and older, who do not speak english * participants who are pregnant as confirmed by medical records

Keywords: acute rejection kidney transplant pediatric biomarker cell free dna
clinical characterization of frequent monogenic forms of neurodevelopmental disorders

Conditions: Neurodevelopmental Disorders

Summary: the main objective is to constitute a precise and exhaustive collection of clinical data (somatic and neurobehavioral data) of individuals affected by various frequent monogenic forms of neurodevelopmental disorders to better characterize the clinical phenotype of these disorders. a better knowledge of these manifestations is necessary to improve the management of individuals with these disorders. the secondary objectives of this research are to inform practitioners, patients and their families about the clinical characteristics of these disorders to better understand their diversity and, finally, to improve their screening and diagnosis. thus, our study aims at establishing clinical scores, linking genotypes and phenotypes and producing documents for professionals (such as the pnds (national diagnostic and care protocols))


Eligibility criteria:
inclusion criteria: * minor patient whose age is ≥ 4 years and ≤18 years * major patient with intellectual disability * patient treated in a participating center for tnd linked to a mutation in one of the genes frequently mutated in this pathology, such as the dyrk1a, kmt2a or other genes; * patient having previously been seen in genetic consultation * parent (or legal guardian) not having expressed, after information, his opposition to the reuse of his data for the purposes of this research. exclusion criteria: - parent (or legal guardian) who expressed his opposition to participating in the study.

Keywords: neurodevelopmental disorders rare disease genetic diseases monogenic syndromes intellectual disability autism spectrum disorder neurobehavioral manifestations
potential impact of patient vitamin d status in ak response to mal-pdt

Conditions: Actinic Keratosis

Summary: in topical photodynamic therapy (pdt) for non-melanoma skin cancers, a photosensitizing prodrug, 5-aminolaevulinic acid (ala) or its methylated ester, methyl aminolevulinate (mal), is converted to the endogenous photosensitizer protoporphyrinix (ppix). reduced response rates are observed in thicker skin lesions, which may be due to insufficient ppix accumulation within the target tissue. to enhance ppix production,several physical and chemical pretreatments have been suggested. one of the chemical substances proposed to stimulate ppix production is vitamin d because of its ability of being a keratinocyte pro-differentiating hormone. based on in vitro and in animal model studies, we propose to study the potential impact of patient vitamin d pre-treatment in ak response to mal-pdt.

a randomized, controlled split -scalp study with calcipotriol assisted mal-pdt versus conventional mal-pdt for actinic keratosis (ak) is proposed. twenty patients ( male gender only) with symmetrically distributed multiple ak lesions on the scalp will be included. patients must have at least five aks per field to be eligible. after simple randomization, one half of the scalp will be treated with calcipotriol ointment 50 mcg/g (daivonex, leo pharma, denmark) for 15 consecutive days. after this period, the entire scalp will be submitted to topical pdt with methylaminolevulinate 16% (metvix, galderma france) under occlusion for 90 minutes and then, illuminated with a light source consisting of a light emitting diode device (led) at 635 nm ( aktilite - photocure, norway). the total light dose will be 37j/cm2. immediately before and after illumination with led, measurements of the fluorescence intensity will be taken in 3 isolated spots in both sides of the scalp with a spectroscopy deviceusb 2000+ ( ocean optics ® - dunedin, fl, usa). ak lesions will be counted and mapped by a dermatologist not involved in the study before and after 3 months. all patients will be advised to apply sunscreens 50 + 3x/day for the following 7 days after the procedure. a 0-10 visual analogue scale (vas) will be used to measure the pain intensity during the illumination. records will be taken after 90 days and compared between sides: side effects, ak lesion response and pain level intensity. also, a long term follow up will be provided at 6 and 12 months after.

Eligibility criteria:
inclusion criteria: * male gender * at least six aks per field exclusion criteria: * history of photosensitivity related disorders * active infectious disease, * immunosuppression * laser or any cosmetic treatment in the previous 6 months * other topical agents in the treatment area such as retinoids, 5-fluorouracil,imiquimod or diclofenac sodium in the previous 3 months * allergy to mal or excipients of the cream * poor patient compliance.

Keywords: pdt skin cancer calcipotriol
resistant hypertension and physical activity performed in a heated pool

Conditions: Hypertension, Resistant to Conventional Therapy

Summary: patients with resistant hypertension will be submitted to an exercise protocol in a heated pool for three months

pacient´s blood pressure behavior will be compared before and after intervention

Eligibility criteria:
inclusion criteria: * patients with uncontrolled blood pressure despite concurrent use of 3 antihypertensive agents, including a diuretic, or the need for more than 3 medications to control blood pressure exclusion criteria: * poor adherence to the treatment * obesity * diabetes * smokers * secondary causes of hypertension * motor disabilities to perform the training

Keywords: resistant hypertension
effect of target temperature management on intestinal flora and its metabolites in patients with cardiac arrest

Conditions: Cardiac Arrest (CA)

Summary: based on the self-control design, this study explored the dynamic regulation of target temperature management therapy (ttm) on intestinal flora structure and metabolites of patients after cardiopulmonary resuscitation (cpr). this study is a single-center prospective observational study. patients with spontaneous circulation recovery (rosc) after cpr and ttm were included before and after self-hypothermia treatment, and the time series changes of intestinal flora and metabolites at some representative time points before and after treatment were compared. thirty-five adult patients (age ≥18 years) who met the admission criteria were included. before ttm treatment (0h after rosc, baseline), 48 h after ttm warming (t1) and 48 h after rewarming (t2), fecal samples (macro-gene sequencing) and blood samples (metabonomics) were collected to analyze the changes of intestinal flora and metabolites in patients with cardiac arrest, and to screen the differential flora and metabolites regulated by ttm and their dynamic correlation.


Eligibility criteria:
inclusion criteria: * (1).18 years old and above; (2) successful resuscitation after cardiopulmonary resuscitation (including chest compressions, electric shock defibrillation, etc.) and target temperature management; exclusion criteria: * (1) pregnant or lactating women; (2) patients with intestinal dysfunction: including severe acute intestinal injury, intestinal obstruction or other diseases that affect the normal function of the intestine; (3) immunosuppression status: such as patients who use immunosuppressants, or patients with obvious immune dysfunction (such as hiv infection, organ transplant patients, etc.); (4) those who have recently undergone intestinal surgery or endoscopy; (5) the patient or his family failed to sign the informed consent or refused to participate in the study;

Keywords: cardiac arrest intestinal flora intestinal metabolites macrogenome